Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's ...
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings
On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H ...
artsatl11h
Flutist Adam W. Sadberry will honor a Civil Rights hero, his grandfather, at Spivey Hall
The Georgia-born musician never knew his grandfather but was inspired to develop a musical program based on the courageous man’s life and career as a journalist during the Civil Rights Movement. Adam ...
Strategic Focus and BMY Collaboration Bolster Prime Medicine’s Financial Outlook: Hold Rating Affirmed
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating today. Terence Flynn’s ...
Jim Wilson's Gemma Biotherapeutics gets up to $100M in funding
Gemma Biotherapeutics, one of two companies launched by former University of Pennsylvania gene therapy program director Dr.
Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil
Research scientist Jim Wilson’s new gene therapy venture, Gemma Biotherapeutics, will receive up to $100 million from Brazil’s Ministry of Health for research designed to bring treatments for rare ...
CTV News6d
David Eby reacts to B.C. billionaire Chip Wilson's pre-election op-ed
B.C. NDP Leader David Eby slammed his billionaire constituent Chip Wilson – again – on the campaign trail, following the ...
HELLO! Magazine13d
Rebel Wilson
Gallery 19 surprise stars who have been spotted attending Taylor Swift's Eras Tour — from Nicole Kidman to Jennifer Garner The likes of Nicole Kidman, Jennifer Garner, Prince William and ...
Eagle-Tribune10d
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease,
On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE ...